Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR422459 in Stargardt's Macular Degeneration
NCT01367444Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2011
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of SAR422459 in Stargardt disease (STGD), sponsored by Sanofi. Started Jun 2011; status: terminated.
02
Drugs
SAR422459
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT01367444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01367444.